Orion OYJ (OTCMKTS:ORINY) Trading 2% Higher - Here's Why

Key Points

• Orion OYJ shares rose by 2% during trading, reaching a last traded price of $38.95, with trading volume increasing by 32% from the average.
• The company reported a net margin of 22.61% and a return on equity of 38.68%, with quarterly earnings of $0.33 EPS and revenue of $472.57 million.
• Orion OYJ operates in the pharmaceutical sector, providing various prescription drugs and self-care products for multiple health conditions, including cancer and Parkinson’s disease.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) was up 2% during trading on Tuesday . The company traded as high as $38.95 and last traded at $38.95. Approximately 322 shares traded hands during trading, an increase of 32% from the average daily volume of 244 shares. The stock had previously closed at $38.18.

Orion OYJ Trading Up 2.0%

The company has a market cap of $10.99 billion, a PE ratio of 26.50 and a beta of 0.11. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.05 and a current ratio of 1.86. The company has a 50 day simple moving average of $39.36 and a two-hundred day simple moving average of $34.15.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last posted its quarterly earnings results on Friday, July 18th. The company reported $0.33 EPS for the quarter. Orion OYJ had a net margin of 22.61% and a return on equity of 38.68%. The business had revenue of $472.57 million during the quarter. Sell-side analysts forecast that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current year.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.